title: Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study.
abstract: In a phase I study, a range of doses of etoposide (200-370 mg/m2 given i.v. daily on 3 consecutive days) were evaluated for tolerance and response as first-line treatment in 26 patients with non-small-cell lung cancer. The dose-limiting toxicity was myelosuppression, especially leukopenia. At dose levels of 350 and 370 mg/m2 etoposide per day, leukopenia of WHO grade 4 occurred in two and one of seven patients, respectively. No thrombocytopenia of this degree was observed. Myelosuppression was quickly reversible and noncumulative. Apart from alopecia, nonhematologic organ toxicities above WHO grade 2 were not seen. Toxicity analysis suggests that the recommended dose of single-agent etoposide for phase II studies in untreated patients is 330-370 mg/m2 given i.v. daily for 3 days. At the dose levels tested, 6 (23%) major responses could be induced. All responses were seen at a starting dose of greater than 300 mg/m2 per day. The median duration of response was 4 months. The median survival for all patients was 8 months and that for responding patients was 15 months.
authors.affiliation: Innere Universitätsklinik und Poliklinik, Essen, Federal Republic of Germany.
authors.forename: N
authors.initials: N
authors.lastname: Niederle
authors.forename: J
authors.initials: J
authors.lastname: Ostermann
authors.forename: W
authors.initials: W
authors.lastname: Achterrath
authors.forename: L
authors.initials: L
authors.lastname: Lenaz
authors.forename: C G
authors.initials: CG
authors.lastname: Schmidt
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013997:Time Factors
chemical_list: D005047:Etoposide